The 11G7 monoclonal antibody specifically binds to human CD282, which is also known as Toll-like receptor 2 (TLR2). CD282 is expressed on monocytes, granulocytes, and dendritic cells. Toll-like receptors (TLRs) play a critical role in antimicrobial resistance. Moreover, TLRs have been shown to activate a number of signal transduction pathways which lead to the induction of genes involved in host defense. TLRs are type-1 transmembrane receptors characterized by the presence of extracellular leucine-rich repeat and intracellular Toll/IL-1 receptor domains. At least 12 mammalian TLRs have been identified, each recognizing a distinct bacterial or viral pathogen-associated molecular pattern, termed PAMP. Peptidoglycan from Gram-positive bacteria, lipoproteins and lipopeptides from several bacteria, glycophosphatidylinositol, lipoarabinomannan, porins, and zymosan from yeast have been reported to be the ligands for TLR2.
It has been reported that mAb 11G7 inhibits the production of inflammatory cytokines via certain TLR2 ligands including TLR2/TLR1 ligands, lipoarabinomannan and PAM3CSK4. However, 11G7 antibody does not inhibit the production of inflammatory cytokines with zymosan, a TLR2/TLR6 ligand. Please note that this application has not been tested at BD Biosciences Pharmingen.
The antibody was conjugated to BD Horizon BV421 which is part of the BD Horizon Brilliant™ Violet family of dyes. With an Ex Max near 407 nm and Em Max near 421 nm, BD Horizon BV421 can be excited by the violet laser (405 nm) and detected with a 450/50 nm filter. BD Horizon BV421 conjugates are very bright, often exhibiting a 10 fold improvement in brightness compared to Pacific Blue™ conjugates. Due to nearly identical excitation and emission properties but different spillover characteristics, BD Horizon BV421, Pacific Blue™, and BD Horizon V450 cannot be used simultaneously.